We’d love to hear your feedback on this activity. It helps us to continually improve our products.
It was a pleasure to meet with Jerry Mendell (Nationwide Children’s Hospital, Columbus, OH, USA) to discuss his recent work in the gene-delivery clinical trial of rAAVrh74.MHCK7.micro-dystrophin (SRP-9001) for Duchenne Muscular Dystrophy. The abstract entitled: ‘A Multicenter Randomized, Double-Blind, Placebo-Controlled, Gene-Delivery Clinical Trial of rAAVrh74.MHCK7.micro-dystrophin for Duchenne Muscular Dystrophy’ was presented at the American Academy […]
It was a great pleasure to meet with Kimford Meador (Stanford University, Stanford, CA, USA) to discuss the effects and use of antiseizure medications during pregnancy, in women with epilepsy. The abstract entitled: ‘Fetal Antiseizure Medication Effects on Neuropsychological Outcomes at Age 3 Years in the MONEAD Study’ was presented at the American Academy of […]
It was a great pleasure to meet with Kimford Meador (Stanford University, Stanford, CA, USA) to discuss the aims, design and preliminary findings from the MONEAD study, and what these results mean for treatment of epilepsy in pregnant women. The abstract entitled: ‘Fetal Antiseizure Medication Effects on Neuropsychological Outcomes at Age 3 Years in the […]
It was a great pleasure to catch up with Susan Hutchinson (Orange County Migraine & Headache Center, Irvine, CA, USA) to discuss her recent study evaluating the safety and tolerability of rimegepant in adults with CV risk factors, for the prevention and treatment of migraine. The abstract entitled: ‘Oral Rimegepant 75 mg is Safe and […]
TouchNEUROLOGY met with Raul Martinez-Fernandez (University Hospital HM Puerta del Sur, Móstoles, Spain) to discuss the recent trial investigating focused ultrasound subthalamotomy and it’s role in the management of Parkinson’s Disease. The abstract entitled: ‘Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson’s Disease’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021. […]
touchNEUROLOGY caught up with Jeffrey Cummings (University of Nevada, Las Vegas, NV, USA) one of our Editorial Board Members, to discuss BAN2401’s use in early stage Alzheimer’s Disease, and Amyloid Related Imaging Abnormalities (ARIA)-E alterations and their utility in amyloid-modifying trials. The abstract entitled: ‘Preliminary Analysis Of BAN2401 Effects On Brain Amyloid And ARIA-E Findings […]
touchNEUROLOGY caught up with Jeffrey Cummings (University of Nevada, Las Vegas, NV, USA) one of our valued Editorial Board Members, to discuss the open-label extension of the Phase 2b Study (BAN2401-G000-201) in subjects with early Alzheimer’s Disease. The abstract entitled: ‘Preliminary Analysis Of BAN2401 Effects On Brain Amyloid And ARIA-E Findings Over 12 Months Of […]
It was a pleasure to interview Sabrina Paganoni (Harvard Medical School, Boston, MA, USA) to discuss treatment options for the management of amyotrophic lateral sclerosis (ALS). The abstract entitled: ‘Long-Term Survival of Participants in the CENTAUR Trial of AMX0035 for ALS’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021. Questions: Could […]
It was a pleasure to meet with Sabrina Paganoni (Harvard Medical School, Boston, MA, USA) to discuss the CENTAUR study findings, and where AMX0035 is likely to be placed in the treatment paradigm for amyotrophic lateral sclerosis (ALS). The abstract entitled: ‘Long-Term Survival of Participants in the CENTAUR Trial of AMX0035 for ALS’ was presented […]
Get the latest clinical insights from touchNEUROLOGY